Open AccessTherapeutic options in the management of acromegaly: focus on lanreotide Autogel®
Author(s) -
Ferdinand Roelfsema,
Nienke R. Biermasz,
Alberto M. Pereira,
Johannes A. Romijn
Publication year - 2008
Publication title -
biologics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 38
eISSN - 1177-5491
pISSN - 1177-5475
DOI - 10.2147/btt.s3356
Subject(s) - acromegaly , lanreotide , medicine , pegvisomant , somatostatin , octreotide , hypopituitarism , gastroenterology , growth hormone , endocrinology , hormone
In acromegaly, expert surgery is curative in only about 60% of patients. Postoperative radiation therapy is associated with a high incidence of hypopituitarism and its effect on growth hormone (GH) production is slow, so that adjuvant medical treatment becomes of importance in the management of many patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom